|
[1]
|
McEvoy, J.W., McCarthy, C.P., Bruno, R.M., Brouwers, S., Canavan, M.D., Ceconi, C., et al. (2024) 2024 ESC Guidelines for the Management of Elevated Blood Pressure and Hypertension. European Heart Journal, 45, 3912-4018. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Sliwa, K., Stewart, S. and Gersh, B.J. (2011) Hypertension. Circulation, 123, 2892-2896. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Rapsomaniki, E., Timmis, A., George, J., Pujades-Rodriguez, M., Shah, A.D., Denaxas, S., et al. (2014) Blood Pressure and Incidence of Twelve Cardiovascular Diseases: Lifetime Risks, Healthy Life-Years Lost, and Age-Specific Associations in 1.25 Million People. The Lancet, 383, 1899-1911. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Vrijens, B., Antoniou, S., Burnier, M., de la Sierra, A. and Volpe, M. (2017) Current Situation of Medication Adherence in Hypertension. Frontiers in Pharmacology, 8, Article 100. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Ma, D., Zhou, Q., Yu, J., Xu, C., Yang, L. and Ning, L. (2026) The U-Shaped Correlation between the Systemic Immune-Inflammation Index and All-Cause and Cardiovascular Mortality in Hyperlipidemic Patients: Findings from NHANES 1999-2018. Annals of Medicine, 58, Article ID: 2656098. [Google Scholar] [CrossRef]
|
|
[6]
|
Ning, B., Chen, Y., Waqar, A.B., Yan, H., Shiomi, M., Zhang, J., et al. (2018) Hypertension Enhances Advanced Atherosclerosis and Induces Cardiac Death in Watanabe Heritable Hyperlipidemic Rabbits. The American Journal of Pathology, 188, 2936-2947. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Mechanick, J.I., Farkouh, M.E., Newman, J.D. and Garvey, W.T. (2020) Cardiometabolic-Based Chronic Disease, Adiposity and Dysglycemia Drivers. Journal of the American College of Cardiology, 75, 525-538. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Chong, B., Jayabaskaran, J., Jauhari, S.M., Chia, J., le Roux, C.W., Mehta, A., et al. (2025) The Global Syndemic of Modifiable Cardiovascular Risk Factors Projected from 2025 to 2050. JACC, 86, 165-177. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
王若楠. 甘油三酯、空腹血糖及甘油三酯葡萄糖乘积指数与高血压发病风险的前瞻性队列研究[J]. 中华流行病学杂志, 2021, 42(3): 482-487.
|
|
[10]
|
Meeks, K.A.C., Bentley, A.R., Agyemang, C., Galenkamp, H., van den Born, B.H., Hanssen, N.M.J., et al. (2023) Ancestral and Environmental Patterns in the Association between Triglycerides and Other Cardiometabolic Risk Factors. eBioMedicine, 91, Article ID: 104548. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Kunutsor, S.K., Connelly, M.A., Shah, A., Bakker, S.J.L. and Dullaart, R.P.F. (2025) Associations of High-Density Lipoprotein Cholesterol, Particles and Subspecies with the Risk of Hypertension: Findings from the PREVEND Prospective Study. Journal of Hypertension, 43, 1066-1074. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
杨婷玉, 安雪梅, 洪忠曦, 等. 中国居民糖尿病、高血压、高血脂共病患病率的Meta分析[J]. 数理医药学杂志, 2025, 38(8): 611-619.
|
|
[13]
|
Tassew, W.C., Woldie, S.S., Ferede, Y.A., Zeleke, A.M. and Nigussie, A. (2025) Dyslipidemia and Associated Factors among Hypertensive Patients in Ethiopia: A Systematic Review and Meta-Analysis. BMC Cardiovascular Disorders, 25, Article No. 367. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
胡杰, 宗丹, 闵婕, 等. 血脂异常与高血压发病风险关系的横断面及孟德尔随机化研究[J]. 心电与循环, 2025, 44(2): 159-163.
|
|
[15]
|
Liang, G., Zhang, W., Gu, X., Zhang, Q., Liu, A., Qing, X., et al. (2024) A Non-Linear Association of Low-Density Lipoprotein Cholesterol with All-Cause and Cardiovascular Mortality among Patients with Hypertension. Frontiers in Cardiovascular Medicine, 11, Article 1469848. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Yan, T., Li, L., Zhang, Z., Cao, N., Xia, Y., Shen, Y., et al. (2025) Low-Density Lipoprotein Cholesterol Reductions of Not Less than 60 mg/dl Prevent Hemorrhagic Stroke in Hypertensive Populations: A Meta-Analysis. Reviews in Cardiovascular Medicine, 26, Article 36363. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Lyu, L.L., Zhu, W.J., et al. (2025) Correlation Analysis of the Circadian Rhythmicity of Blood Pressure with Ox-LDL/β2GPI Complex and Carotid Atherosclerosis in Patients with Essential Hypertension. Chinese General Practice, 28, 2228-2233. (In Chinese)
|
|
[18]
|
Thangasparan, S., Kamisah, Y., Ugusman, A., Mohamad Anuar, N.N. and Ibrahim, N. (2024) Unravelling the Mechanisms of Oxidised Low-Density Lipoprotein in Cardiovascular Health: Current Evidence from in Vitro and in Vivo Studies. International Journal of Molecular Sciences, 25, Article 13292. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Wu, J. and Guo, J. (2024) Non-High-Density Lipoprotein Cholesterol to High-Density Lipoprotein Cholesterol Ratio (NHHR) and Hypertension in American Adults: A NHANES Cross-Sectional Study. Frontiers in Physiology, 15, Article 1398793. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Sheng, G., Kuang, M., Yang, R., Zhong, Y., Zhang, S. and Zou, Y. (2022) Evaluation of the Value of Conventional and Unconventional Lipid Parameters for Predicting the Risk of Diabetes in a Non-Diabetic Population. Journal of Translational Medicine, 20, Article No. 266. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Carr, S.S., Hooper, A.J., Sullivan, D.R. and Burnett, J.R. (2019) Non-HDL-Cholesterol and Apolipoprotein B Compared with LDL-Cholesterol in Atherosclerotic Cardiovascular Disease Risk Assessment. Pathology, 51, 148-154. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Qi, X., Wang, S., Huang, Q., Chen, X., Qiu, L., Ouyang, K., et al. (2024) The Association between Non-High-Density Lipoprotein Cholesterol to High-Density Lipoprotein Cholesterol Ratio (NHHR) and Risk of Depression among US Adults: A Cross-Sectional NHANES Study. Journal of Affective Disorders, 344, 451-457. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Hurtubise, J., McLellan, K., Durr, K., Onasanya, O., Nwabuko, D. and Ndisang, J.F. (2016) The Different Facets of Dyslipidemia and Hypertension in Atherosclerosis. Current Atherosclerosis Reports, 18, Article No. 82. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Chen, M., Zhang, L., Liu, Q., Gu, Q., Yu, S. and Lu, G. (2025) Non-high Density Lipoprotein Cholesterol/High Density Lipoprotein Cholesterol Is L-Shaped Associated with All-Cause Mortality and U-Shaped with Cardiovascular Mortality in Hypertensive Patients. Frontiers in Endocrinology, 16, Article 1490229. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Su, X., Rao, H., Zhao, C., Wu, J., Zhang, X. and Li, D. (2025) Association between the Non-High-Density Lipoprotein Cholesterol to High-Density Lipoprotein Cholesterol Ratio and Mortality among Hypertension Patients. Scientific Reports, 15, Article No. 6012. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Dobiásová, M. and Frohlich, J. (2000) [The New Atherogenic Plasma Index Reflects the Triglyceride and HDL-Cholesterol Ratio, the Lipoprotein Particle Size and the Cholesterol Esterification Rate: Changes during Lipanor Therapy]. Vnitrni Lekarstvi, 46, 152-156.
|
|
[27]
|
duiyimuhan, G. and Maimaiti, N. (2023) The Association between Atherogenic Index of Plasma and All-Cause Mortality and Cardiovascular Disease-Specific Mortality in Hypertension Patients: A Retrospective Cohort Study of NHANES. BMC Cardiovascular Disorders, 23, Article No. 452. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Mo, D., Zhang, P., Zhang, M., Dai, H. and Wang, G. (2025) Association between the Atherogenic Index of Plasma and Incident Hypertension across Different Blood Pressure States: A National Cohort Study. Cardiovascular Diabetology, 24, Article No. 219. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Tan, M., Zhang, Y., Jin, L., Wang, Y., Cui, W., Nasifu, L., et al. (2023) Association between Atherogenic Index of Plasma and Prehypertension or Hypertension among Normoglycemia Subjects in a Japan Population: A Cross-Sectional Study. Lipids in Health and Disease, 22, Article No. 87. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Chowdhury, R., Warnakula, S., Kunutsor, S., Crowe, F., Ward, H.A., Johnson, L., et al. (2014) Association of Dietary, Circulating, and Supplement Fatty Acids with Coronary Risk: A Systematic Review and Meta-Analysis. Annals of Internal Medicine, 160, 398-406. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Takiwaki, M., Tomoda, F., Koike, T., Taki, T., Inoue, H., Kigawa, M., et al. (2014) Increased Levels of Small Dense Low-Density Lipoprotein Cholesterol Associated with Hemorheological Abnormalities in Untreated, Early-Stage Essential Hypertensives. Hypertension Research, 37, 1008-1013. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Tanaka, M., Sato, T., Endo, K., Inyaku, M., Mori, K., Hosaka, I., et al. (2023) An Increase in Calculated Small Dense Low-Density Lipoprotein Cholesterol Predicts New Onset of Hypertension in a Japanese Cohort. Hypertension Research, 46, 2635-2645. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Młynarska, E., Bojdo, K., Frankenstein, H., Krawiranda, K., Kustosik, N., Lisińska, W., et al. (2025) Endothelial Dysfunction as the Common Pathway Linking Obesity, Hypertension and Atherosclerosis. International Journal of Molecular Sciences, 26, Article 10096. [Google Scholar] [CrossRef]
|
|
[34]
|
Dina, C., Tit, D.M., Radu, A., Bungau, G. and Radu, A. (2025) Obesity, Dietary Patterns, and Cardiovascular Disease: A Narrative Review of Metabolic and Molecular Pathways. Current Issues in Molecular Biology, 47, Article 440. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Ye, Z., Li, Y., Yang, X., Li, C., Yu, R., Zheng, G., et al. (2025) Targeting Regulation of Macrophage to Treat Metabolic Disease: Role of Phytochemicals. Cell Proliferation, 58, e70012. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Verreth, W., De Keyzer, D., Pelat, M., Verhamme, P., Ganame, J., Bielicki, J.K., et al. (2004) Weight Loss-Associated Induction of Peroxisome Proliferator-Activated Receptor-α and Peroxisome Proliferator-Activated Receptor-γ Correlate with Reduced Atherosclerosis and Improved Cardiovascular Function in Obese Insulin-Resistant Mice. Circulation, 110, 3259-3269. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Rochlani, Y., Pothineni, N.V., Kovelamudi, S. and Mehta, J.L. (2017) Metabolic Syndrome: Pathophysiology, Management, and Modulation by Natural Compounds. Therapeutic Advances in Cardiovascular Disease, 11, 215-225. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Fahed, G., Aoun, L., Bou Zerdan, M., Allam, S., Bou Zerdan, M., Bouferraa, Y., et al. (2022) Metabolic Syndrome: Updates on Pathophysiology and Management in 2021. International Journal of Molecular Sciences, 23, Article 786. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Hamooya, B.M., Siame, L., Muchaili, L., Masenga, S.K. and Kirabo, A. (2025) Metabolic Syndrome: Epidemiology, Mechanisms, and Current Therapeutic Approaches. Frontiers in Nutrition, 12, Article 1661603. [Google Scholar] [CrossRef]
|
|
[40]
|
Wensveen, F.M., Valentić, S., Šestan, M., Turk Wensveen, T. and Polić, B. (2015) The “Big Bang” in Obese Fat: Events Initiating Obesity‐induced Adipose Tissue Inflammation. European Journal of Immunology, 45, 2446-2456. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Costa, G.S., Julião-Silva, L.S., Belo, V.S., de Oliveira, H.C.F. and Chaves, V.E. (2022) A Systematic Review and Meta-Analyses on the Effects of Atorvastatin on Blood Pressure and Heart Rate. European Heart Journal—Cardiovascular Pharmacotherapy, 9, 100-115. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Besekar, S., Jogdand, S. and Patel, S.S. (2025) Hypotensive Effects of Statins: A Rapid Review. Journal of Clinical and Diagnostic Research, 19, FE01-FE07. [Google Scholar] [CrossRef]
|
|
[43]
|
Toghi, C.J., Martins, L.Z., Pacheco, L.L., Caetano, E.S.P., Mattos, B.R., Rizzi, E., et al. (2023) Pravastatin Prevents Increases in Activity of Metalloproteinase-2 and Oxidative Stress, and Enhances Endothelium-Derived Nitric Oxide-Dependent Vasodilation in Gestational Hypertension. Antioxidants, 12, Article 939. [Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
Deedwania, P., Murphy, S.A., Scheen, A., Badariene, J., Pineda, A.L., Honarpour, N., et al. (2021) Efficacy and Safety of PCSK9 Inhibition with Evolocumab in Reducing Cardiovascular Events in Patients with Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis from the FOURIER Randomized Clinical Trial. JAMA Cardiology, 6, 139-147. [Google Scholar] [CrossRef] [PubMed]
|
|
[45]
|
Ray, K.K., Colhoun, H.M., Szarek, M., et al. (2019) Effects of Alirocumab on Cardiovascular and Metabolic Outcomes after Acute Coronary Syndrome in Patients with or without Diabetes: A Prespecified Analysis of the ODYSSEY OUTCOMES Randomised Controlled Trial. The Lancet. Diabetes & Endocrinology, 7, 618-628.
|
|
[46]
|
Brandts, J. and Ray, K.K. (2021) Clinical Implications and Outcomes of the Orion Phase Iii Trials. Future Cardiology, 17, 769-777. [Google Scholar] [CrossRef] [PubMed]
|
|
[47]
|
Ostadal, P., Steg, P.G., Poulouin, Y., Bhatt, D.L., Bittner, V.A., Chua, T., et al. (2022) Metabolic Risk Factors and Effect of Alirocumab on Cardiovascular Events after Acute Coronary Syndrome: A Post-Hoc Analysis of the ODYSSEY OUTCOMES Randomised Controlled Trial. The Lancet Diabetes & Endocrinology, 10, 330-340. [Google Scholar] [CrossRef] [PubMed]
|
|
[48]
|
Olmastroni, E., Scotti, S., Galimberti, F., Xie, S. and Casula, M. (2024) Ezetimibe: Integrating Established Use with New Evidence—A Comprehensive Review. Current Atherosclerosis Reports, 27, Article No. 10. [Google Scholar] [CrossRef] [PubMed]
|
|
[49]
|
Wan, S., Ding, Y., Ji, X. and Meng, R. (2021) The Safety and Efficacy of Ezetimibe Plus Statins on ASVD and Related Diseases. Aging and disease, 12, 1857-1871. [Google Scholar] [CrossRef] [PubMed]
|
|
[50]
|
Mahajan, K., Nagendra, L., Dhall, A. and Dutta, D. (2024) Impact of Early Initiation of Ezetimibe in Patients with Acute Coronary Syndrome: A Systematic Review and Meta-Analysis. European Journal of Internal Medicine, 124, 99-107. [Google Scholar] [CrossRef] [PubMed]
|
|
[51]
|
Drexel, H., Tamargo, J., Kaski, J.C., Lewis, B.S., Saely, C.H., Fraunberger, P., et al. (2023) Triglycerides Revisited: Is Hypertriglyceridaemia a Necessary Therapeutic Target in Cardiovascular Disease? European Heart Journal—Cardiovascular Pharmacotherapy, 9, 570-582. [Google Scholar] [CrossRef] [PubMed]
|
|
[52]
|
Das Pradhan, A., Glynn, R.J., Fruchart, J., MacFadyen, J.G., Zaharris, E.S., Everett, B.M., et al. (2022) Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. New England Journal of Medicine, 387, 1923-1934. [Google Scholar] [CrossRef] [PubMed]
|